Moderna's Stock Performance: Moderna, Inc. (NASDAQ: MRNA) is listed among the 13 best S&P 500 stocks to buy according to Wall Street analysts, despite experiencing a year-to-date decline of over 35% in its share price in 2025.
Challenges Faced: The company has faced difficulties post-pandemic, including a decrease in demand for COVID-19 vaccines and regulatory delays affecting its product pipeline, leading to a lowered revenue forecast for 2025.
Analyst Sentiment: While analysts maintain a consensus Hold rating on Moderna's stock, they note an attractive one-year average share price upside potential, indicating possible recovery as clinical progress continues.
Investment Comparison: Despite the potential of Moderna as an investment, some analysts suggest that certain AI stocks may offer greater upside potential with less downside risk.
MRNA
$29.89+Infinity%1D
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 40.13 USD with a low forecast of 17.00 USD and a high forecast of 198.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
Wall Street analysts forecast MRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 40.13 USD with a low forecast of 17.00 USD and a high forecast of 198.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
13 Hold
4 Sell
Hold
Current: 29.920
Low
17.00
Averages
40.13
High
198.00
Current: 29.920
Low
17.00
Averages
40.13
High
198.00
Wells Fargo
Equal Weight -> Overweight
upgrade
$22
2025-12-16
New
Reason
Wells Fargo
Price Target
$22
2025-12-16
New
upgrade
Equal Weight -> Overweight
Reason
Wells Fargo upgraded Monte Rosa Therapeutics to Overweight from Equal Weight with a $22 price target.
Morgan Stanley
Equal Weight
downgrade
$30 -> $28
2025-12-12
New
Reason
Morgan Stanley
Price Target
$30 -> $28
2025-12-12
New
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on Moderna to $28 from $30 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
Jefferies
Hold
initiated
$30
2025-12-11
Reason
Jefferies
Price Target
$30
2025-12-11
initiated
Hold
Reason
Jefferies initiated coverage of Moderna with a Hold rating and $30 price target. For 2026, the company's Covid and RSV sales should grow ex-US with operating expense also falling about 8%, but while this is directionally helpful, Moderna will need more to meet guide, the analyst tells investors in a research note. Moderna's pipeline also needs to progress to drive non-Covid revenue to $3B, the firm added.
Piper Sandler
Overweight
to
NULL
downgrade
$69 -> $63
2025-11-21
Reason
Piper Sandler
Price Target
$69 -> $63
2025-11-21
downgrade
Overweight
to
NULL
Reason
Piper Sandler lowered the firm's price target on Moderna to $63 from $69 and keeps an Overweight rating on the shares. The firm notes Moderna laid out growth plans driven by mNEXSPIKE in 2026; mRNA-1010, intismeran and European growth in 2027; and mRNA-1083 and mRNA-1403 in 2028. Piper projects product sales of $1.73B in 2025 to grow to $2.15B in 2026.
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
